Kairos Pharma, Ltd. (KAPA)
AMEX · Healthcare
$0.32+3.81%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $7.28M
- P/E ratio
- —
- EPS
- —
- Volume
- 1,142,055
- 52-week high
- —
- 52-week low
- —
- Open
- $0.31
- Day high
- $0.34
- Day low
- $0.30
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$5.45M | -$0.30 |
| 2024 | — | -$2.6M | -$0.23 |
| 2023 | — | -$1.81M | -$0.17 |
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
- CEO
- John S. Yu
- Employees
- 4
- Country
- US
- IPO date
- Sep 16, 2024
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Kairos Pharma, Ltd.'s stock price today?
- KAPA is trading at $0.32 as of Jul 20, 2026.
- What is Kairos Pharma, Ltd.'s market cap?
- Kairos Pharma, Ltd. (KAPA) has a market capitalization of $7.28M.
- Does Kairos Pharma, Ltd. pay a dividend?
- Kairos Pharma, Ltd. did not pay a dividend in its most recent reported fiscal year.
- What sector is Kairos Pharma, Ltd. in?
- Kairos Pharma, Ltd. operates in the Healthcare sector.